Identification of the Factors That Govern the Ability of Therapeutic Antibodies to Provide Postchallenge Protection Against Botulinum Toxin: A Model for Assessing Postchallenge Efficacy of Medical Countermeasures against Agents of Bioterrorism and Biological Warfare
Open Access
- 17 May 2011
- journal article
- research article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in The Journal of pharmacology and experimental therapeutics
- Vol. 338 (2), 503-517
- https://doi.org/10.1124/jpet.111.180653
Abstract
Therapeutic antibodies are one of the major classes of medical countermeasures that can provide protection against potential bioweapons such as botulinum toxin. Although a broad array of antibodies are being evaluated for their ability to neutralize the toxin, there is little information that defines the circumstances under which these antibodies can be used. In the present study, an effort was made to quantify the temporal factors that govern therapeutic antibody use in a postchallenge scenario. Experiments were done involving inhalation administration of toxin to mice, intravenous administration to mice, and direct application to murine phrenic nerve-hemidiaphragm preparations. As part of this study, several pharmacokinetic characteristics of botulinum toxin and neutralizing antibodies were measured. The core observation that emerged from the work was that the window of opportunity within which postchallenge administration of antibodies exerted a beneficial effect increased as the challenge dose of toxin decreased. The critical factor in establishing the window of opportunity was the amount of time needed for fractional redistribution of a neuroparalytic quantum of toxin from the extraneuronal space to the intraneuronal space. This redistribution event was a dose-dependent phenomenon. It is likely that the approach used to identify the factors that govern postchallenge efficacy of antibodies against botulinum toxin can be used to assess the factors that govern postchallenge efficacy of medical countermeasures against any agent of bioterrorism or biological warfare.Keywords
This publication has 21 references indexed in Scilit:
- Localization of the sites and characterization of the mechanisms by which anti-light chain antibodies neutralize the actions of the botulinum holotoxinVaccine, 2009
- Botulinum ToxinPublished by Elsevier BV ,2009
- Development and partial characterization of high-affinity monoclonal antibodies for botulinum toxin type A and their use in analysis of milk by sandwich ELISAJournal of Immunological Methods, 2008
- The Role of Systemic Handling in the Pathophysiologic Actions of Botulinum ToxinThe Journal of pharmacology and experimental therapeutics, 2008
- Creation and Development of the Public Service Orphan Drug Human Botulism Immune GlobulinPEDIATRICS, 2007
- The Use of Small Molecules to Investigate Molecular Mechanisms and Therapeutic Targets for Treatment of Botulinum Neurotoxin A IntoxicationACS Chemical Biology, 2006
- An Initial Assessment of the Systemic Pharmacokinetics of Botulinum ToxinThe Journal of pharmacology and experimental therapeutics, 2006
- Human Botulism Immune Globulin for the Treatment of Infant BotulismThe New England Journal of Medicine, 2006
- Structural Features of the Botulinum Neurotoxin Molecule That Govern Binding and Transcytosis across Polarized Human Intestinal Epithelial CellsThe Journal of pharmacology and experimental therapeutics, 2004
- The Role of the Interchain Disulfide Bond in Governing the Pharmacological Actions of Botulinum ToxinThe Journal of pharmacology and experimental therapeutics, 2003